160 related articles for article (PubMed ID: 33915156)
1. A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer.
Liu X; Hu Q; Wang W; Ma H; Pu J; Cui J; Gong T; Wu Y; Lu W; Huang J
Biochem Pharmacol; 2021 Jun; 188():114583. PubMed ID: 33915156
[TBL] [Abstract][Full Text] [Related]
2. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
3. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
4. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
5. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
8. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
[TBL] [Abstract][Full Text] [Related]
9. Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.
Chigira T; Nagatoishi S; Tsumoto K
Biochem Biophys Res Commun; 2015 Aug; 463(4):726-31. PubMed ID: 26049107
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogenic Activity of the Xi-Huang Formula for Breast Cancer by Targeting the Estrogen Receptor α.
Hao J; Jin Z; Zhu H; Liu X; Mao Y; Yang X; Gao L; Liu D; Chen D; Wu X
Cell Physiol Biochem; 2018; 47(6):2199-2215. PubMed ID: 29975948
[TBL] [Abstract][Full Text] [Related]
11. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
Zhao Y; Laws MJ; Guillen VS; Ziegler Y; Min J; Sharma A; Kim SH; Chu D; Park BH; Oesterreich S; Mao C; Shapiro DJ; Nettles KW; Katzenellenbogen JA; Katzenellenbogen BS
Cancer Res; 2017 Oct; 77(20):5602-5613. PubMed ID: 28904064
[TBL] [Abstract][Full Text] [Related]
12. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α.
Jang SY; Jang SW; Ko J
Cancer Lett; 2011 Jan; 300(1):57-65. PubMed ID: 20934245
[TBL] [Abstract][Full Text] [Related]
13.
Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
[TBL] [Abstract][Full Text] [Related]
14. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
[TBL] [Abstract][Full Text] [Related]
15. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
16. Activating
Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
[TBL] [Abstract][Full Text] [Related]
17. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
19. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL
Elife; 2018 Nov; 7():. PubMed ID: 30489256
[TBL] [Abstract][Full Text] [Related]
20. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
